Wisevoter
South San Francisco

Deep Origin Joined Forces With BioAge Labs

The two firms have entered a multi-target collaboration to accelerate drug discovery using computational and wet lab methods.

Updated on Oct. 14, 2026 in Biotech

Bold vector editorial illustration of a glass beaker containing molecular shapes next to a platform, representing the drug discovery partnership.
Biotech firms Deep Origin and BioAge Labs have launched a collaborative drug discovery partnership to accelerate therapy development via computational platforms. AI Illustration. Upload story photo >

Live Poll

Do you believe artificial intelligence will successfully accelerate the development of new medicines?

South San Francisco companies Deep Origin and BioAge Labs have partnered to develop treatments against novel targets. BioAge Labs has already successfully validated functional hits identified by Deep Origin for its initial target.

Why it matters

The collaboration aims to shorten drug development timelines by combining computational drug discovery platforms with functional laboratory verification. By merging these capabilities, the firms hope to expedite the search for effective therapies.

Deep Origin utilizes a proprietary virtual screening architecture based on its DODock and DOScore platforms. In a recent study, this approach achieved a 30.6% hit rate against the CD73 target.

The players

Deep Origin

This biotechnology firm uses computational drug discovery platforms to identify potential small-molecule hits.

BioAge Labs

This clinical-stage company focuses on developing therapeutics for aging-related diseases.

The details

Deep Origin uses its computational platform to identify small-molecule hits, which BioAge Labs then tests in its wet lab to ensure functional activity. This partnership has already pushed the first target into the hit-to-lead optimization phase.

Timeline

  1. Deep Origin published its virtual screening methods in a preprint in August 2026.

  2. The collaboration between Deep Origin and BioAge Labs was announced on October 14, 2026.

  3. BioAge expects to release Phase 2 cardiovascular proof-of-concept data in the second half of 2026.

  4. BioAge anticipates reporting Phase 2 diabetic macular edema data in the second half of 2027.

The Tech Race

This collaboration highlights the growing reliance on computational virtual screening architectures like DODock and DOScore to replace slower traditional drug discovery methods. By integrating these platforms, companies aim to maintain a competitive advantage in the race to identify novel therapeutic leads.

While these developments are currently in the research phase, successful drug discovery efforts from partnerships like this could eventually bring new, targeted therapies to market. For patients, these computational approaches may lead to faster development timelines for treatments addressing complex medical conditions.

The takeaway

The integration of AI-driven virtual screening with laboratory validation is becoming a standard strategy for accelerating pharmaceutical pipelines. Companies that successfully bridge this gap may significantly reduce the time and capital required to reach human clinical trials.

What happens next

BioAge expects to report Phase 2 cardiovascular proof-of-concept data in the second half of 2026 and Phase 2 diabetic macular edema data in the second half of 2027.

Further reading

Learn more about local industry trends in our Biotech section.

Source note: This article includes information reported by The Manila times.

Live Poll

Do you believe artificial intelligence will successfully accelerate the development of new medicines?